Roche snags postsurgery FDA nod for Alecensa, eyes even broader lung cancer use
Roche isn’t content with Alecensa being the best-selling ALK inhibitor in metastatic lung cancer. The Swiss pharma has now secured FDA approval in the post-surgical setting as it continues to test the drug in additional patient populations. The FDA has …